417 related articles for article (PubMed ID: 32039239)
1. Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.
Audebrand A; Désaubry L; Nebigil CG
Front Cardiovasc Med; 2019; 6():194. PubMed ID: 32039239
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.
Morelli MB; Bongiovanni C; Da Pra S; Miano C; Sacchi F; Lauriola M; D'Uva G
Front Cardiovasc Med; 2022; 9():847012. PubMed ID: 35497981
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review.
Destere A; Merino D; Lavrut T; Rocher F; Viard D; Drici MD; Gérard AO
Therapie; 2024; 79(2):161-172. PubMed ID: 37957054
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
7. Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.
Chan SHY; Khatib Y; Webley S; Layton D; Salek S
Front Pharmacol; 2023; 14():1137983. PubMed ID: 37383708
[No Abstract] [Full Text] [Related]
8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
9. The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity.
Zhang X; Gao Y; Yang B; Ma S; Zuo W; Wei J
Int Immunopharmacol; 2023 Apr; 117():109895. PubMed ID: 36806040
[TBL] [Abstract][Full Text] [Related]
10. A Patent Review on Cardiotoxicity of Anticancerous Drugs.
Bhadana R; Rani V
Cardiovasc Hematol Agents Med Chem; 2023 Jan; ():. PubMed ID: 36683367
[TBL] [Abstract][Full Text] [Related]
11. [Development of Preventive Methods for Drug-induced Cardiotoxicity Using a Large-scale Medical Information Database].
Hamano H; Zamami Y; Ushio S; Niimura T; Goda M; Izawa-Ishizawa Y; Ishizawa K
Yakugaku Zasshi; 2024; 144(3):257-264. PubMed ID: 38432934
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
13. Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia.
Badheeb AM; Ahmed F; Alzahrani HA; Badheeb MA; Obied HY; Seada IA
Cureus; 2023 Jul; 15(7):e41287. PubMed ID: 37533611
[TBL] [Abstract][Full Text] [Related]
14. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of ghrelin and des-acyl ghrelin against chemotherapy-induced cardiotoxicity.
Nonaka M; Kurebayashi N; Murayama T; Sugihara M; Terawaki K; Shiraishi S; Miyano K; Hosoda H; Kishida S; Kangawa K; Sakurai T; Uezono Y
Endocr J; 2017; 64(Suppl.):S35-S39. PubMed ID: 28652542
[TBL] [Abstract][Full Text] [Related]
16. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost.
Efentakis P; Andreadou I; Iliodromitis KE; Triposkiadis F; Ferdinandy P; Schulz R; Iliodromitis EK
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430599
[TBL] [Abstract][Full Text] [Related]
17. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.
Perpinia AS; Kadoglou N; Vardaka M; Gkortzolidis G; Karavidas A; Marinakis T; Papachrysostomou C; Makaronis P; Vlachou C; Mantzourani M; Farmakis D; Konstantopoulos K
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015155
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing chronic kidney disease and hypertension increased the risk of cardiotoxicity among colorectal cancer patients treated with anticancer drugs.
Ho CC; Wen PC; Yu WC; Hu YW; Yang CC
J Chin Med Assoc; 2021 Sep; 84(9):877-884. PubMed ID: 34320515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
